NRSNW
NeuroSense Therapeutics Ltd. WarrantKey Statistics
About NeuroSense Therapeutics Ltd. Warrant
NeuroSense Therapeutics Ltd. is an innovative biotechnology company dedicated to developing advanced therapies for neurodegenerative diseases, particularly focusing on amyotrophic lateral sclerosis (ALS). The company's lead therapeutic candidate addresses pivotal mechanisms underlying disease progression, potentially offering groundbreaking treatment options. NeuroSense employs a multi-modal approach that integrates various therapeutic strategies, setting it apart in the competitive neurotherapeutics market. Committed to clinical development and scientific rigor, NeuroSense is poised to significantly impact the biopharmaceutical landscape, enhancing the quality of life for patients suffering from severe neurological disorders.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.07M |
| Operating Margin | 0.00% |
| Return on Equity | -2175.00% |
| Return on Assets | -247.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.05 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $23.34M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NRSNW and any ticker you trade — then tracks every position and per-strategy win rate.